AVACTA GROUP PLC
AVACTA GROUP PLC ORD 10P AVCT.L · LSE
Live GBP 0.64 ▼ 0.01 (0.78%)
Mkt Cap £277.90M
Volume 1,195,898
52W 48.00 – 92.00
🔔 Sign in to receive sentiment alerts for AVACTA GROUP PLC.
Market Sentiment
Sentiment Grade
B
↑ Improving (+28.9 pts vs 7-day avg)
Movement is measured on the underlying −100 to +100 sentiment scale — +28.9 pts is about +1.4 on the /10 score above.
AVACTA GROUP PLC
Positive Sentiment
6.6/10
Sentiment Index
Very NegativeNeutralVery Positive
79%
Avg Confidence
54 / 7
Positive / Negative articles
📰 Based on 100 articles from 32 sources TradingView ×18 This Site ×11 Kalkine Media ×10 uk.finance.yahoo.com ×7 Yahoo Finance ×6
📊 Moderate volatility — MEVI 20.1/100
🕐 Updated 10 hours ago
📋 Today's context
Daily AI-generated context for this company — recent events, market backdrop, and supporting developments. Available to Pro Investor members.
Sentiment Distribution
Sentiment Trend
Latest RNS & Market News
- AVACTA GROUP PLC – Notice Of Interim Results Investor MeetingRNS Number : 4502Y Avacta Group PLC 12 October 2026 Avacta Group plc (“Avacta” or the “Group” or the “Company”) Notice of Interim Results Investor Meeting LONDON and PHILADELPHIA – October 12, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted…
- AVACTA GROUP PLC – Capital Access WindowRNS Number : 8582W Avacta Group PLC 30 September 2026 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH…
- AVACTA GROUP PLC – Further Demonstration Of Potential Of Ava6103RNS Number : 2487W Avacta Group PLC 25 September 2026 Avacta Group plc (“Avacta” or the “Company”) The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer LONDON and PHILADELPHIA – September 25, 2026 – Avacta Therapeutics (AIM:…
- AVACTA GROUP PLC – Pre Cision Platform Wins R D Achievement AwardRNS Number : 2500W Avacta Group PLC 25 September 2026 Avacta Group plc (“Avacta” or the “Company”) The pre|CISION® Platform Wins Research and Development Achievement Award from Pharma Industry Awards UK 2026 LONDON and PHILADELPHIA – September 25, 2026 – Avacta Therapeutics (AIM: AVCT, the “Company”, “Avacta”), a…
- AVACTA GROUP PLC – Clinical Proof Of Mechanism For Precision PlatformRNS Number : 9116U Avacta Group PLC 16 September 2026 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH…